myasthenia gravis association
MGA
of the heartland

Strength and Hope Through CONNECTIONS

Volume 60 Issue 1
Winter 2020

Diana Wilmoth retires as St. Luke's Hospital MGA Clinic Volunteer Coordinator

For nearly 20 years, patients who came to St. Luke's on the Plaza or South in Kansas City to see Dr. Michael Schwartzman also had the privilege to also see Diana Wimoth, RN. Diana has worn just about every hat for the MGA but is most recognized for her role in initiating the MG Clinic at St. Luke's where she has supported and empowered patients and their families from the time they entered the office building to the time they zipped up their coats to leave. Diana created a clinic culture built on the desire to educate those impacted to ensure they get the best possible care. In the early years, clinic was not as busy as it is today which often boosts a clinic sometimes filled with 5-6 patients.

At the time of her MG diagnosis, Diana was in her forties, Assistant Director of Nursing at St. Luke's Hospital. After diagnosis and due to complications with her MG, she was not able to continue in her position. The decision to step out of her Clinic Volunteer Coordinator role was no lighthearted decision for Diana. Like the advice Diana shares most often with patients, there comes a time when you must care for yourself.

The MG Clinic at St. Luke's is held twice a month. Patients coming to see Dr. Schwartzman at the MG Clinic will now be greeted by Tanya Renner, Program Coordinator for the MGA. The MGA appreciates everybody's patience as we transition. We are forever grateful for Diana's leadership for the last 20 years. Enjoy your retirement, Diana!

MGA partners with St. Louis University for MG Clinic

New year, new clinic. In case you hadn't heard, the MGA opened a MG clinic in St. Louis in partnership with Saint Louis University Hospital! The clinic had been in the works for quite some time, and with the support of our board and SLUcare physicians, we were able to officially introduce the clinic on January 7th, 2020. In hopes to further extend our advocacy work to our patients within the St. Louis area, the clinic will serve as a closer and more personal resource for our MG community.

Heading the clinic is fellow MG patient and social worker Meridith O'Connor. Meridith has been a part of this community for more than 15 years and with her extensive background in healthcare and personal experience with MG, we believe she will be a great asset to not only our team but to all the patients we assist. Meridith stated, "I am truly honored to have been offered the opportunity to work as the program coordinator for MGA in St. Louis. As someone who has Myasthenia Gravis, I know what it takes to fight this disease and feel that I can help other patients and families in a unique way." Ultimately, we foresee Meridith facilitating communication, fostering relationships, and serving as a direct resource for our MG patients and families in this particular role.

This is an exciting enterprise for the MGA and we are optimistic that the MG clinic in St. Louis will be a successful one. If you have any further questions regarding the STL clinic, please don't hesitate to contact us. Here's to new beginnings!

Specialty Pharmacy & Home Infusion

ARJ ReadyPack®

We thoughtfully organize each ReadyPack® with patients and caregivers in mind.

Benefits

- **Supplies for every infusion**
- **Easy-to-read labels**
- **Travel-friendly packaging**

The ARJ Advantage

Our pharmacists are happy to expedite medication right to your home or doctor's office.

24/7 Nationwide Care

866-451-8804
arjinfusion.com

ARJ Infusion SERVICES

A MESSAGE FROM THE MGA'S EXECUTIVE DIRECTOR



It feels a tad funny to let this roll off my tongue, but it's an exciting time for those with myasthenia gravis. Yep, you read that. I just said that! And I know what you are thinking, how can it be an exciting time when you are living with a debilitating chronic illness that some days knocks the wind out of your sails? It's an exciting time because the MG community is finally getting some attention. As you will read through much of this edition, the focus is on Clinical Trials. We would be doing you a disservice not to share with you what is going on in the world of Clinical Trials and the opportunities you have for possible treatments. Opportunities and choices. Opportunities for you and I to feel better, to breathe easier, to swallow easier, to speak easier, to see better. Better days are coming. I can just feel it! Speaking of exciting, we are holding our first ever MG Educational Seminar in St. Louis on World Rare Disease Day, Leap Day, Saturday February 29, 2020. As well as, we are rolling out two new groups to offer support, our Topeka Area Support Group and our Eastsiders Lunch Bunch. I encourage you to become involved. We hope you enjoy this issue of Connections. Have an idea for us? We'd love to hear from you– allisonfoss@mgakc.org.

MGA Board of Directors and Staff

Meridith O'Connor, MSW joins the MGA as Program Coordinator for St. Louis

You likely read our exciting news about the addition of our St. Louis Clinic at SLU on page 1. We are excited to introduce you to our new Program Coordinator for St. Louis, Meridith O'Connor. Meridith was diagnosed with generalized Myasthenia Gravis at the young age of 13 and has been managing her illness since 2005. In spite of the physical limitations MG has brought forth, Meridith continues to live a very fulfilling life. In 2014, Meridith graduated from Saint Louis University with a Bachelor of Arts degree in psychology with a minor in healthcare ethics. In 2018, Meridith earned her master's degree in social work with a concentration in health from the Brown School at Washington University in St. Louis. Meridith has utilized her academic background and personal experience with chronic illness to advocate for others going through similar situations. Meridith also serves as a writer, speaker and entrepreneur in the chronic illness community and works diligently to support people with invisible disabilities. When not busy working, Meridith enjoys spending time with her close friends and family, volunteering for various nonprofits, and daydreaming about all things fashion.

In This Issue

Share with us!

We want to see your wins, your celebrations, your victories, big or small, what you are up to! Send us your pictures and any stories you may have about your life with MG. We are sprucing up our social media and our website and looking for items to share. You can send any to allisonfoss@mgakc.org

LEAP IN AND LEARN

MYASTHENIA GRAVIS EDUCATIONAL SEMINAR

featuring information about clinical trials and the newly approved drug, eculizumab (Soliris)

Celebrate World Rare Disease Day With us!

SATURDAY FEBRUARY 29TH
8:30AM-1PM

8:30 AM | CHECK IN/CONTINENTAL BREAKFAST
9:00 AM | OPENING REMARKS FROM THE MGA AND GHAZALA HAYAT, MD
9:15 AM | CLINICAL TRIALS OVERVIEW PRESENTED BY ANGELA PONTIUS, RA PHARMACEUTICALS
ST. LOUIS UNIVERSITY CLINICAL TRIALS UPDATES BY JAFAR KAFAIE, MD
10:45 AM | ECULIZUMAB PRESENTATION
12:00 PM | LUNCH

COURTYARD BY MARRIOTT
8101 DALE AVENUE, RICHMOND HEIGHTS, MO

RSVP REQUIRED TO TANYA RENNER BY 2/20/20
TANYARENNER@MGAKC.ORG OR 816-256-4100

FREE TO ATTEND!

myasthenia gravis association
MGA
of the heartland

ARJ Infusion SERVICES

Momenta
Driven by impossible

Ra Pharma

Topeka Area Support Group Forming

You spoke, we listened! We are excited to share that a Topeka Area Support Group has been formed and will begin meeting quarterly. Nicole Riedy, mom to Shane who was diagnosed with MG at age 2 Iwill be leading the group. Join us for our inaugural meeting on Thursday February 20th from 6-8pm at Beanheads Coffee House, 2525 NW Topeka Blvd, Topeka. Allison Foss, Executive Director of the MGA will speak about her lifelong journey with MG. Please RSVP by February 14th, 2020 to Tanya Renner, tanyarenner@mgakc.org.

Eastsiders Lunch Bunch Forming

Do you live on the Eastside of Kansas City? Do you like to go to lunch? Are you or a family member impacted by myasthenia gravis? Do you like to meet others? If you answered “yes” to any of these questions we have a new group for you! Carol Hunt, newly diagnosed with MG approached the MGA about starting a group local to the her in Oak Grove. Collectively, we came up with the Eastsiders Lunch Bunch! This will be a social group, meeting on the 3rd Wednesday of each month at 11am. The first meeting will be Wednesday March 18th at 11am at Smokehouse BBQ in Indepdence, MO. For more information please contact the MGA tanyarenner@mgakc.org or Carol at carolhunt04@yahoo.com.

59th Annual Meeting of the MGA held

Nearly 100 patients, family members, friends and providers gathered on November 9, 2019 to learn about Clinical Trials and celebrate the 59th year of the MGA. A panel moderated by John Sand, MD consisted of Angela Pontius of Ra Pharma, Mamatha Pasnoor, MD, University of Kansas and Meredith Martin, Patient. The panel covered everything from why participate in a clinical trial to what clinical trials are currently available to those with MG. You’ll want to continue reading through this newsletter for more clinical trial updates. This years award winners were Stephanie Hubers, Volunteer of the Year and the Iowa State Alumni Club of Kansas City received Stackhouse Award. The MGA also revealed the Diana Wilmoth Sunflower Award which will be given a person who has shown extraordinary service to the MGA through leadership, volunteerism and spirit. Diana Wilmoth, herself was the first recipient of the award. The MGA is appreciative of all those who participated in the Annual Meeting including this years five vendors, ARJ Infusion Services, Superior Biologics, Momenta, argenx and Ra Pharma. Go ahead and save the date for November 7, 2020 for the 60th Annual Meeting of the MGA!

Help us celebrate MG Awareness Month this June by attending our 3rd Annual MGA Snowflake Shuffle in Wichita on 6.13.20. More info at www.mgakc.org

MGA SNOWFLAKE SHUFFLE
0.1k Run
6.13.2020 Wichita, KS

Clinical Trials

Kansas University Medical Center in Kansas City, KS, is participating in clinical trials relating to myasthenia gravis (see below). If you are interested in participating in a trial or would like more information, go to clinicaltrials.gov, and enter the NCT number related to the specific trial. You can also call KU directly and talk to Andrew Heim at 913-945-9926. See our detailed article about these clinical trials beginning on page 7.

1. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults with Generalized Myasthenia Gravis NCT03772587

2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis NCT03920293

3. Characterization of Agrin/LRP4 Antibody Positive Myasthenia Gravis. Visit http://www.augusta.edu/research/studies/view.php?study=713470 for more information on this study

4,. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients with Generalized Myasthenia Gravis NCT03971422

5. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis NCT04115293

For Clinical Trials at **St. Louis University** contact 314-977-4900 for more information.
St. Louis University is recruiting for pediatrics for the Soliris trial.

For Clinical Trials at the **University of Missouri** contact Raghav Govindarajan, MD at Govindarvindarajanr@health.missouri.edu

What is the MGA Triple Crown Showdown?

The MGA Triple Crown Showdown is the signature awareness event of the Myasthenia Gravis Association, which features a 5K Run/Walk, Mile Mosey and Tot Trot for the kids. It is always held the 3rd weekend in May in conjunction with the Preakness Race and is derby themed. It is a morning of raising awareness and funds for those impacted by myasthenia gravis. All funds raised stay locally in the Heartland!

Who?

You! The MGA Triple Crown Showdown is open to all so grab your friends, family and register. As our VIP's, those living with myasthenia gravis are invited to register for FREE using the code MGA20. Not up for running or walking? No problem. We have a vendor area where you can enjoy breakfast, kids activities, raffles and mingle with others while raising awareness of myasthenia gravis. Can't make it in person? Sign up for "Stuck in the Stall" and virtually participate. We'll even mail you a shirt following the event.

Why?

Who doesn't love raising awareness of myasthenia gravis? It's our 10th year and we want you there!

www.mga5k.com

SUNDAY MAY 17, 2020
8AM
Town Center Plaza,
Leawood, KS

Status of Myasthenia Gravis Research Trials 2020 and Beyond!

By: Mamatha Pasnoor, MD & Mazen M. Dimachkie, MD
Neuromuscular Division Research Program
Department of Neurology
The University of Kansas Medical Center (KUMC)

There have been so many advances in research in order to improve the care of people with Myasthenia gravis (MG) and many more are on the horizon. For many decades the mainstay of MG treatment has been corticosteroids. Other immunosuppressive drugs were introduced and most of these medications were used either to treat other autoimmune conditions such as rheumatoid arthritis or to prevent transplanted organs rejection. There is now a great interest in development of new targeted treatments specific to people with MG based on an enhanced understanding of the cause of MG and the biology of immunoglobulins (Ig).

Recently two novel mechanisms are being evaluated; complement inhibition (this is how we think eculizumab works in MG) and blocking the neonatal Fc receptor (FcRn). The latter is important for the recycling of Ig back out from the cell into the blood stream and blocking the FcRn results in reduction of Ig levels. Most of these studies currently use MG activities of daily living (MGADL) questionnaire not only for including patients in the study but also to assess whether the treatment helps improve MG. This instrument, amongst others, was developed by Laura Herbelin and Dr. Richard J. Barohn of the KUMC.

Our team recently completed a North American study led by Dr. Dimachkie evaluating the role of subcutaneous Ig in MG patients who were already on IVIg. We have recently participated as a site in the ARGX-113-1704 and ARGX-113-1705 studies which explore an agent blocking the FcRn. This study is currently closed to enrollment.

However, several more studies are open to enrollment. These are available for people with MG who want to advance discovery by participating in those studies. Given the distance factor (some of our research subjects come to use from 200 miles away or even longer distances), many of these studies offer a small compensation to offset cost of travel expenses. While the Neuromuscular Division Research Program members conduct their own research studies in MG and disseminate their publications, below is a summary of studies currently going on here in Kansas City that are actively seeking volunteers for research participation. These are funded either by pharmaceuticals companies or by the NIH:

MycarinGstudy

Sponsor: UCB Pharma
This is a phase 3 randomized, double blind , placebo controlled study looking at the efficacy and safety of Rozanolixizumab in patients with generalized MG. Rozanolixizumab is a subcutaneously administered, humanized monoclonal antibody that specifically binds, with high affinity, to human FcRn and designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies. Patients will receive 2 different dosages of the drug or placebo. The medication is given subcutaneously (under the skin instead of IV).
Total number of participants to be enrolled: 240 by March 2021
Criteria to enroll: Patients must have generalized MG with either AChR antibody positive or MUSK positive MG. MGADL at least 3, QMG at least 11 and MGFA class II to IVa at baseline.
The primary outcome is MGADL at day 43 compared to baseline. Other secondary outcomes are also looked at.
An open label extension study for participants completing the MycarinGstudy is available by searching the internet with the key word NCT04124965.

MOM-M281-004

Sponsor: Momenta Pharmaceuticals
This is a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 in Generalized Myasthenia Gravis. M281 targets the neonatal FC receptor (FcRn) IgG binding site with high affinity, thereby interfering with the binding of native IgG. In cells of the reticuloendothelial system, FcRn binding of IgG protects it from degradation and contributes to its long half-life. Interference with FcRn function leads to a decrease in IgG levels including the pathogenic autoantibodies that cause MG.

The primary objectives are to evaluate the safety and tolerability of treatment with M281 injection in patients with generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing, stable standard of care therapy.
Total number of patients 60 and up to 30 additional patients.
Criteria to enroll: MUSK or AChR antibody positivity, MGFA class II, III or IVa at screening, QMG ≥ 12.
The efficacy of M281 injection for gMG is measured by the change in MGADL score.
Upon completion of the study, patients have the option to enroll in MOM-M281-005, a separate open-label extension study where they would receive treatment with M281 injection. Duration of treatment is 8 weeks.

RAISE Study

Sponsor: Ra Pharmaceutical
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan (RA101495) in Subjects with Generalized Myasthenia Gravis.
Zilucoplan is a potent, synthetic macrocyclic peptide inhibitor of complement C5 which is convenient self-administered daily subcutaneous injection. Planned enrollment is 130 patients, completion in April 2021
Criteria to enroll: Diagnosis of generalized MG, positive AChR Antibodies, MGADL score of ≥ 6 at screening and baseline, QMG ≥ 12 and stable does of steroid for at least 30 days. Patients must be vaccinated against meningococcus. Primary outcome: Change in MG-ADL score from Baseline to week 12

Continued on the next page….

MSK-002

Sponsor: Catalyst Pharmaceuticals

A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in 60 patients with Muscle Specific Tyrosine Kinase (MUSK) Antibody Positive Myasthenia Gravis, and 10 patients with AChR Antibody Positive Myasthenia Gravis. Amifampridine is a non-specific voltage-dependent potassium (K^+) channel blocker which causes depolarization of the presynaptic membrane and slows down or inhibits repolarization. Prolonged depolarization results in opening of slow voltage-dependent calcium (Ca^{2+}) channels and allows a subsequent influx of Ca^{2+}. The increased concentration of intracellular Ca^{2+} induces release of the synaptic vesicles containing ACh, thus releasing an increased level of ACh into the synaptic cleft. The influx of ACh into the presynaptic cleft enhances neuromuscular transmission, providing improved muscle function. This was approved for Lambert Eaton Myasthenic patients. Most common adverse events: perioral and peripheral paresthesias and gastrointestinal disorders (abdominal pain, nausea, diarrhea). Other side effects include rare seizures, cardiac arrhythmias, QTc prolongation on EKG. This is an oral pill taken daily.

Criteria to enroll: MGADL at screening should be greater than or equal to 6 to be included in this study. The primary objective is to see the safety and efficacy compared to placebo of Amifampridine in MUSK -MG patients based on change in MGADL. This study requires 14 days of screening and up to 45 days of participation with only 4-5 clinic visits of approximately 1 hour each.

MSK-003 is the extension phase of this study where all patients are on the medication for at least 9 months

ALXN1210

Sponsor: Alexion pharmaceuticals

This is a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in patients with generalized MG. Ravulizumab like eculizumab (soliris) binds to complement component (C5), inhibiting C5 enzymatic cleavage and thereby preventing the generation of the proinflammatory/ prothrombotic complement activation products, C5a, and the cytolytic and proinflammatory/prothrombotic membrane attack complex, C5b-9, which are responsible for the antibody-mediated destruction of the neuromuscular junction (NMJ), loss of acetylcholine receptors, and failure of neuromuscular transmission associated with generalized myasthenia gravis (gMG). Ravulizumab was designed to have increased half-life relative to eculizumab. Therefore, ravulizumab requires less frequent (once every 8 weeks) infusions than eculizumab. Intravenous (IV) infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight. Treatment period 26 weeks and open labelled extension is 2 years. Total 120-140 sites will be participating in this trial. Total number of patients 160.

Criteria to enroll: Generalized MG MGADL ≥ 6. Primary end point is change in MGADL at 26 weeks. Study was started in March 2019, expected completion in 2021.

LRP4

This is an NIH funded study with PI Dr Lin Mai from Georgia Regents University. It is available to MG patients in the Kansas City area as we are a participating site. Characterization of Agrin/ LRP4 Antibody Positive Myasthenia Gravis. This study collaborates with 27 MG Centers in the United States. This study evaluates new autoantibodies that might explain symptoms in this population of patients. In addition to collecting samples from seronegative MG patients, samples from other disease and normal controls was also collected to check the specificity of these antibodies to MG. The study will provide investigators the information of the prevalence of antibodies to Agrin and LRP4 in antibody negative patients and will tell how specific these antibodies are for MG. The clinical information might enable us to correlate patient symptoms to the pathological actions of their antibodies. This information will help to correlate Agrin and LRP4 antibodies to the degree of severity of MG based on the QMG score.

This report is developed on behalf of our research team at the KUMC. In addition to Drs. Pasnoor and Dimachkie, faculty members of this research team are Laura Herbelin, and Drs. Richard J. Barohn, Omar Jawdat, Jeffrey Statland, Constantine Farmakidis and Duaa Jabari. We could not do these research studies without our superb and dedicated team of research coordinators, clinical evaluators, project managers and our excellent collaborators at the KUMC – Research Institute. We are thankful most of all to patients with MG who are willing to change their lives' routine and participate in our studies. To contact us and inquire about research participation, please reach out to: Ayla McCalley amccalley@kumc.edu , Andrew Heim aheim@kumc.edu or Betty Criss 913-945-9935.

We are currently exploring participation in other MG targeted therapies. This really is an exciting time for the field of MG with all of the ongoing research clinical trials and the promise of novel discoveries that will improve the lives of people with MG and of their support care team.

MG 101: What is Myasthenic Crisis? Myasthenic crisis happens when the respiratory muscles get too weak to move enough air in and out of the lungs. The patient is unable to breathe and a machine (ventilator) is needed to help breathe for the patient. The ventilator may do this through a tube into the airway (endotracheal intubation) or a tight-fitting mask on the face (Bi-PAP). Myasthenic crisis involves only the respiratory muscles so it is different from an MG flare (exacerbation). An MG flare is worsening of some or all muscles throughout the body, not just the muscles used for breathing. MG flares vary from patient to patient but may include worsened double vision, increased arm weakness, falling, unsteady walking, and having a hard time swallowing. *(taken from materials of Sally O'Meara, RN, MGFA Nurses Advisory Board)*

MG Support Groups

Area	Dates	Time	Location
Kansas City, MO	February 8th	10am-12:00pm	**St. Joseph Medical Center ~ Community Center** 1000 Carondelet Drive Kansas City, MO 64114 RSVP tanyarenner@mgakc.org or (816) 256-4100
KC Northland	March 12th	noon-1:30pm	**Primrose Retirement Communities** 8559 N Line Creek Pkwy Kansas City, MO 64151 RSVP tanyarenner@mgakc.org or (816) 256-4100
Mid-Missouri	February 27th	6:30-8pm	Services for Independent Living– note location change 1401 Hathman Place Columbia, MO 65201 RSVP tanyarenner@mgakc.org or (816) 256-4100
Springfield, MO	April 30th	6-8pm	**The Library Center** 4653 S. Campbell Springfield, MO 65810 RSVP tanyarenner@mgakc.org or (816) 256-4100
St. Louis	February 29th	8:30am 1:00pm	Courtyard by Marriott-Brentwood 8101 Dale Avenue Richmond Heights, MO RSVP tanyarenner@mgakc.org or 816-256-4100
Wichita, KS	April 18th	1-3pm	**Via Christi St. Francis Hospital** 929 N. St. Francis St. Wichita, KS 67214 Contact: Dana or Larry Paxson for more info or to RSVP dkptiffany@gmail.com or (316) 269-9120
Young Friends of the MGA Group– Kansas City	February 25th	6pm	**Dave and Busters– the Legends** 1843 Village West Parkway Kansas City, KS 66109 RSVP to Allison Foss allisonfoss@mgakc.org
Young Persons with MG Group-STL	March 25	6pm	**Location TBD** RSVP to Meridith O'Connor meridithoconnor@mgakc.org
Northwest, AR	March 8th	2:30-4:30pm	**Schmieding Center for Senior Health and Education** 2422 N. Thompson (Hwy 71 North) Springdale, AR 72764 Contact: Roger Huff for more info or to RSVP jrhuff1@cox.net or (479) 790-3022
Topeka, KS	February 20th	6-8pm	**Beanheads's Coffee House** 2525 NW Topeka Blvd Topeka, KS 66617 RSVP tanyarenner@mgakc.org or 816-256-4100
Eastsiders Lunch Bunch	March 18th	11am	**Smokehouse BBQ** 19000 East 39th Street Independence, MO 64057 RSVP tanyarenner@mgakc.org or 816-256-4100

Membership Contributions

Julia Kirsch
Robert and Carol Hunt
Larry and Dana Paxson
Robert and Pamela Kennedy
Fred and Suzanne Bartel
Ann Mowry
Donnie Davis
Cindy Disque
Katherine and Michael Cardella
John and Cindy Wilkinson
Mark and Diane Lindsay
Ray and Betsy Olsen
Doris Glover
Jeanette Cashatt
Peter Flanton
Stephen and Debbie Siemieniewski
Charles and Mary Haley
Ed Stambach
Douglas Dible
Pamela Wilson
Sandy and Gary Gardner
Don and Norma Thomas
Richard and Wilma Perry
Ellen Burrough
LaDonna Diller
Ann Dault
Allison Foss
Mary Little
Jimmie Harbour
Larry Keisker
Edsel Noland
Elaine Huntsinger
Vern Grothoff
Nancy and Kenneth Sherbert
Ji and Sun Wei
Jeff and Marla Burvee
Jeffrey and Catherine Schmeltz
Judith Gorsky
Moroj Alhajeri
Robert Sims
Lisa Gioia
Charlas and Jim Bales
Winston Seeman
Kenneth and Diane Cummings
Dorothy Canady
Robert and Sandra Collard
Harold and Donna Riehm
Fred Batts
Dr. Eric May
Becky Hainje
Kelly Hakenwerth
Joel Mouse and Vicki Carrio
Karen and Robert Sims
Gene and Shirley Goode
Derek and Nina Haverkamp
Nancy and Ron Vinsant
Jeremy and Stephanie Hubers
Sally Crowley
Don and Marilyn Sisson
Anita and Everett Jenkins
Dan and Donna Gifford
Hal and Joan Brill
Phyllis Peniston *in honor of Pamela Strucker*
Pete Foiles *in memory of Margaret Foiles*
Linda Hodge i*n memory of Dick Hodge, in honor of Larry Cook, Dick Johnson and Jennie Struble*
Richard and Jan McGuire *in memory of Jacob McGuire, DDS*
Dorothy Antrim *in memory of Margaret Lowrey*
Bruce and Terre Tepikian *in memory Maureen Hall*
McLaughlin Camp #12 *in memory of Jan Eichinger*
Virgie Bivens *in memory of Jan Eichinger*
Gary and Sally Dvorak *in memory of Jan Eichinger*

MGA CONNECTIONS

Are you newly diagnosed and looking for support and answers? Have you lived with MG for years and want to share your experiences? For anyone looking to talk to others who have MG, we have MGA Connections! Give us a call or send us an email and we will send you the full list or help make sugges-

Consider becoming a 2020 member!

PLEASE PRINT **Cut & enclose in envelope & mail to: ➔**

MGA
2340 E. Meyer Blvd.
Bldg.1, Suite 300A
KCMO 64132

Name ______________________________

Address______________________City____________State___Zip______

Phone______________________ Email ______________________

I want to help support the MGA by becoming a 2020 member or making a contribution:

PLEASE CHECK:
- ☐ **MG Patient**
- ☐ **Relative**
- ☐ **Friend**

- ☐ $ 25 Basic Membership
- ☐ $ 60 (*60th Anniversary Membership)*
- ☐ $ 100 Sustaining Membership
- ☐ $ 500 Patron Membership
- ☐ $ 1,000 Lifetime Membership
- ☐ $ _____ In Memory of:
- ☐ $ _____ In Honor of:

Thank You!

Make checks payable to the Myasthenia Gravis Association: CONTRIBUTIONS may be tax deductible

DONATE NOW

https://www.firstgiving.com/event/mgakc/2020MGA

Strength and Hope through Connections

United Way of
Greater Kansas City

Check us out
on the Web:
www.mgakc.org

If you would like to be
removed from
or added to our mailing list,
or if you have or will have an
address change,
please send a note to:
Myasthenia Gravis Association
2340 E. Meyer Blvd.
Building 1, Suite 300A
Kansas City, MO 64132
~ or ~
Call us at: (816) 256-4100

The Mission of the MGA

The Myasthenia Gravis Association (MGA) is dedicated to improving the quality of life for those who are affected by this autoimmune, neuromuscular disease, through awareness, education and patient services.

Myasthenia Gravis Association
2340 E. Meyer Blvd.
Building 1, Suite 300A
Kansas City, MO 64132
Phone: (816) 256-4100
Email: info@mgakc.org
www.mgakc.org
www.mga5k.com